| 摘要: |
| 吡仑帕奈片为FDA批准的首个高选择性非竞争性AMPA受体拮抗剂,治疗癫痫疗效明确且耐受性良好,近年来逐渐成为临床一线用药,其国内仿制药申报逐渐成为热点。本文通过调研相关文献,总结吡仑帕奈片国内外批准上市情况,对该品种药学研究以及多规格生物等效性豁免的主要关注点进行讨论,旨在为相关产品开发提供一定的借鉴。 |
| 关键词: 吡仑帕奈 拮抗剂 癫痫 仿制药 药学研究 |
| DOI:10.13506/j.cnki.jpr.2025.11.008 |
| 基金项目: |
|
Publication Date:November 25, 2025
|
|
| General considerations for the pharmaceutical research of generic drugs of Perampanel Tablets |
| WANG Gongfu,LI Chen |
| (Center for Drug Evaluation, National Medical Products Administration, Beijing 100076, China) |
| Abstract: |
| Perampanel Tablets are the first highly selective noncompetitive AMPA receptor antagonist approved by the FDA, with clear efficacy and good tolerability in the treatment of epilepsy. In recent years, it has gradually become a first-line clinical drug, and its domestic generic drug application has become a hot topic. This article summarized the approved market situation at home and abroad through research on relevant literature, and discusses the main focus of pharmaceutical research and requirement for additional strength biowaiver on this variety, aiming to provide some reference for product development. |
| Key words: Perampanel Antagonist Epilepsy Generic drugs Pharmaceutical research |